{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:01:54Z","timestamp":1776862914402,"version":"3.51.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Both autologous and allogeneic hematopoietic cell transplantation (HCT) have been used to treat high-risk anaplastic large cell lymphoma (ALCL) that has failed conventional chemotherapy. However, many patients are not able to fully eradicate disease prior to HCT, making the role of either form of HCT unclear. The aim of this study was to collect characteristics and outcomes of patients who underwent either autologous and\/or allogeneic HCT and determine the role that disease status at HCT plays in overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To address this, we collected data on 41 patients with ALCL that underwent autologous (n=24) and\/or allogeneic (n=17) HCT at our center between 1997-2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 5-year estimated progression-free survival (PFS) and OS for the autologous HCT group was 40% (95% confidence interval, 20-59%) and 53% (31-71%), while for the allogeneic HCT group it was 65% (38-92%) and 65% (38-82%), respectively. For transplants performed in 2009 or later, 5-year OS  was 91% (51-99%) in the allogeneic HCT group, and  51% (23-73%) in the autologous HCT group. Notable was that for those who entered transplant with detectable disease, 5-year OS was 50% (15-77%) with allogeneic HCT whereas it was 27% (7-54%) for autologous HCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These data confirm that HCT is a potentially curative therapy, and allogeneic HCT may have a survival advantage over autologous HCT when there is detectable disease prior to HCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1785566","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:53:23Z","timestamp":1776858803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Autologous and allogeneic hematopoietic cell transplantation in children and adults with high-risk anaplastic large cell lymphoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Natalie L.","family":"Smith","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Summers","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]},{"name":"Department of Pediatrics, University of Washington School of Medicine","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted","family":"Gooley","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Shustov","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Salit","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]},{"name":"Department of Medicine, University of Washington School of Medicine","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca A.","family":"Gardner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine","place":["Seattle, WA, United States"]},{"name":"Cancer and Blood Disorders Center, Seattle Children's Hospital","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Dahlberg","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]},{"name":"Department of Pediatrics, University of Washington School of Medicine","place":["Seattle, WA, United States"]},{"name":"Cancer and Blood Disorders Center, Seattle Children's Hospital","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Bleakley","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]},{"name":"Department of Pediatrics, University of Washington School of Medicine","place":["Seattle, WA, United States"]},{"name":"Cancer and Blood Disorders Center, Seattle Children's Hospital","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed L.","family":"Sorror","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]},{"name":"Department of Medicine, University of Washington School of Medicine","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leona","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]},{"name":"Department of Medicine, University of Washington School of Medicine","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]},{"name":"Department of Pediatrics, University of Washington School of Medicine","place":["Seattle, WA, United States"]},{"name":"Cancer and Blood Disorders Center, Seattle Children's Hospital","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]},{"name":"Department of Medicine, University of Washington School of Medicine","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Maloney","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]},{"name":"Department of Medicine, University of Washington School of Medicine","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica S.","family":"Thakar","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center","place":["Seattle, WA, United States"]},{"name":"Department of Pediatrics, University of Washington School of Medicine","place":["Seattle, WA, United States"]},{"name":"Cancer and Blood Disorders Center, Seattle Children's Hospital","place":["Seattle, WA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/Blood-2014-10-567461","article-title":"The biology and management of systemic anaplastic large cell lymphoma","volume":"126","author":"Hapgood","year":"2015","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/Jco.2012.42.2345","article-title":"Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'etude des lymphomes de l'adulte trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/Blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (Echelon-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/J.Clml.2013.07.005","article-title":"A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission","volume":"13","author":"Mehta","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/S41409-019-0734-7","article-title":"Autologous hematopoietic stem cell transplantation for relapsed\/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party (LWP) of the EBMT","volume":"55","author":"Domingo-Domenech","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/Jco.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/Sj.Bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell Malignant lymphomas: a BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/Bjh.13167","article-title":"Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan","volume":"168","author":"Fukano","year":"2015","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/Bmt.2009.165","article-title":"Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT Group","volume":"45","author":"Numata","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/Bmt.2015.57","article-title":"Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC","volume":"50","author":"Strullu","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/Jco.2011.34.8417","article-title":"Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study","volume":"29","author":"Woessmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/Ajh.25513","article-title":"Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management","volume":"94","author":"Zain","year":"2019","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/Jamanetworkopen.2021.9807","article-title":"Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Du","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/J.Beha.2013.04.008","article-title":"Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T\/NK-cell lymphomas","volume":"26","author":"Shustov","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.930852","article-title":"Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"56","author":"Illidge","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/Blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/J.Bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/Blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"B21","first-page":"215","article-title":"Who classification of tumours of haematopoietic and lymphoid tissues","volume-title":"World Health Organization Classification of Tumours","author":"Swerdlow","year":"2008"},{"key":"B22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/J.Bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/Jco.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1200\/Jco.20.00157","article-title":"Stem cell transplantation and vinblastine monotherapy for relapsed pediatric anaplastic large cell lymphoma: results of the international, prospective ALCL-relapse trial","volume":"38","author":"Knorr","year":"2020","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/Hon.2560","article-title":"Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin","volume":"37","author":"Chihara","year":"2019","journal-title":"Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/Bmt.2015.280","article-title":"Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"51","author":"Mamez","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/Bjh.18052","article-title":"Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant","volume":"197","author":"Savani","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1785566\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:53:24Z","timestamp":1776858804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1785566\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1785566"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1785566","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1785566"}}